Direct oral anticoagulants versus Vitamin K antagonist in kidney transplant recipients with atrial fibrillation: A study from a global federated research network

European Journal of Internal Medicine 2026 Open access

Read full text
Authors: Michele Rossi, Enrico Tartaglia, Amir Askarinejad, Andrea Galeazzo Rigutini, Muath Alobaida, Anirudh Rao, Louise Oni, Claudio Ferri, Tommaso Bucci, Gregory Y.H. Lip
DOI: 10.1016/j.ejim.2026.106751
Cited by: 4
References: 32

Abstract

BACKGROUND: The risk-benefit profile of direct oral anticoagulants (DOACs) in kidney transplant recipients (KTRs) with atrial fibrillation (AF) remains under-investigated. PURPOSE: To evaluate the safety and efficacy of DOACs compared with vitamin K antagonists (VKAs) in KTRs with AF. METHODS: Retrospective analysis from TriNetX network. Adult KTRs with AF were included. Patients with mechanical valves, antiphospholipid syndrome, or an estimated eGFR

Fields of Study & Subjects

Atrial Fibrillation Management and Outcomes Renal Transplantation Outcomes and Treatments Transplantation: Methods and Outcomes

Publication details

Journal / source
European Journal of Internal Medicine
Publisher
Elsevier BV
Volume
147
Pages
106751–106751
Publication date
7 February 2026
Language
EN